AveXis, Inc.

AveXis, Inc.

AveXis, Inc.

Overview
Date Founded

2010

Headquarters

2275 Half Day Road,Suite 200,Bannockburn, IL 60015

Type of Company

Private

Employees (Worldwide)

219

Industries

Biotechnology
Medical Support Services
Hospitals & Patient Services

Company Description

AveXis, Inc. is a clinical-stage gene therapy company that engages in the research and development of novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its proprietary gene therapy, Zolgensma, is designed to develop treatment of spinal muscular atrophy. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and is headquartered in Bannockburn, IL.

Contact Data
Trying to get in touch with decision makers at AveXis, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Senior Vice President, General Counsel & Chief Compliance Officer

Chief Scientific Officer

Chief Business Officer & Senior Vice President

Senior Vice President & Chief Human Resources Officer

Senior Vice President, Corporate Strategy & Business Development

Chief Regulatory & Quality Officer, Senior Vice President

Vice President, Business Operations

Vice President, Research & Development

President

Senior Director

Paths to AveXis, Inc.
Potential Connections via
Relationship Science
You
AveXis, Inc.
Recent Transactions
Details Hidden

Novartis AG, AveXis, Inc. purchase Astrazeneca Plc /Longmont Manufacturing Operations from AstraZeneca Plc

Details Hidden

Novartis International AG, Novartis AG purchase AveXis, Inc.

Details Hidden

AveXis, Inc. issued USD Common Stock

Transaction Advisors
Investment Advisor

Advised onNovartis International AG, Novartis AG purchase AveXis, Inc.

Escrow Agent

Advised onAveXis, Inc. issued USD Common Stock

Underwriter

Advised onAveXis, Inc. issued USD Common Stock

Legal Advisor

Advised onAveXis, Inc. issued USD Common Stock

Legal Advisor

Advised onAveXis, Inc. issued Common Stock

Legal Advisor

Advised onAveXis, Inc. issued Common Stock

Advisors & Consultants
Publicist

Associate Director at The W2O Group

Key Stats and Financials As of 2017
Market Capitalization
$7.83B
Total Enterprise Value
Earnings Per Share
Revenue
$0
EBITDA
$-218M
Investors
Details Hidden

Deerfield Management Co. focuses on investments in growth stocks across the healthcare sector. They target companies with sound fundamentals, long-term earnings growth potential and the potential to capitalize on market trends. Deerfield's approach is based on extensive fundamental research into healthcare sector assets and investment opportunities. They invest mainly in US companies or companies that issue securities available in US public markets. Although this is their focus, there is no geographic limitation on investments and Deerfield may invest outside the US when situations warrant. Their funds generally pursue one of 3 strategies: Large-Cap, Special Situations and Private Design.Deerfield's Large-Cap strategy invests mainly in debt and equity securities, including exchange traded derivative securities, of publicly-traded companies in the healthcare sector. The strategy seeks capital appreciation through a combination of security selection based on fundamental analysis, diversification through investments in stock, debt and derivatives and a mix of long and short positions.The firm's Special Situations strategy emphasizes investments in publicly traded healthcare companies with smaller market-caps. At least 90% of investments must in healthcare companies, and essentially all investments are healthcare related. Investments include equity, debt, royalties or other assets, some of which may have limited liquidity. The strategy makes both long and short investments and may utilize leverage.Deerfield's Private Design strategy invests in public and private healthcare companies using privately created instruments, structures and transactions. This may include, but is not limited to, joint ventures, project financing, contracting for revenue streams, purchasing products/services outright (including intellectual property), participating in LBOs, restructurings and outright buyouts, and developing/participating in the development and sale of therapeutics, medical devices and healthcare products/services.

Details Hidden

ACM manages the Adage Capital Partners Fund (ACP). The firm seeks to achieve its objective through stock selection based primarily on intra-industry fundamental analysis with a dedicated focus on intra-industry valuation methodologies. Primary research is a central component of their investment process. ACM utilizes a staff of portfolio managers and equity analysts dedicated to tracking specific sectors represented within the Index that utilize a stock valuation methodology designed for each specific sector in selecting the investments of ACP. The firm currently utilizes one non-industry specific analyst, focusing on risk arbitrage opportunities for ACP. They may employ additional analysts and/or portfolio managers in the future, focusing on non-industry specific methodologies for identifying investments for ACP, and in connection with such methodologies ACM may cause ACP engage in additional types of investments, such as leveraged trading and/or risk arbitrage or other event driven trading.

Details Hidden

Roche Venture Fund seeks investments in innovative technology oriented companies with the focus on biotechnology and medicine.

Suppliers
REGENXBIO, Inc. Biotechnology | ROCKVILLE, MD

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Nationwide Children's Hospital Hospitals & Patient Services | COLUMBUS, OH

Nationwide Children's Hospital engages in the provision of pediatric health care services. It specializes in otolaryngology services, gastroenterology, hepatology and nutrition, hematology, oncology and blood and marrow transplant, neurology, and sports medicine. The company was founded in 1892 and is headquartered in Columbus, OH.

Asklepios BioPharmaceutical, Inc. Holding Companies | Research Triangle Park, NC

Asklepios BioPharmaceutical, Inc. engages in the development and delivery of novel protein and cellular based therapies through design of proprietary Biological Nano Particles (BNP). The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila Mikhail in 2003 and is headquartered in Research Triangle Park, NC.

Competitors
Biogen, Inc. Biotechnology - San Diego, CA

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Roche Holding AG Pharmaceuticals - Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Ionis Pharmaceuticals, Inc. Pharmaceuticals - Carlsbad, California

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by AveXis, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of AveXis, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and AveXis, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/avexis-inc-130904747
  • https://relationshipscience.com/organization/avexis-inc-130904747